ABBV

Since its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarship Now a renewable award, students may earn the AbbVie Immunology Scholarship for up to four years Recipients live with conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis NORTH CHICAGO, Ill., Aug. 18, 2026 /PRNewswire/ --  AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology Scholarship, as the program marks its 10th year.

AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both delivered strong quarters, but they tell very different dividend stories.

The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout.

Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

I'm going to put our year-end call on the table before anything else. Our AbbVie (NYSE:ABBV | ABBV Price Prediction) year-end verdict is a buy, and our proprietary model sees more room to run despite the stock already sitting near record highs.